Clinical Trial

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-28.
Trial Details
NCT Number NCT07008664
Lead Sponsor University of Maryland, Baltimore
Collaborators: EPOCH Epigenetics, Inc
Conditions Lung Cancer, Lung Cancer Screening, Healthy Volunteers (HV), Unhealthy Volunteers
Enrollment 750 participants
Start Date 2025-03-31
Primary Completion 2031-04 (estimated)
Study Completion 2032-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-29